In cases of NSCLC with common EGFR mutations such as Ex19del and L858R, EGFR-tyrosine kinase inhibitors (TKIs) such as osimertinib play a pivotal role in the treatment regimens for palliative chemotherapy [2,3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.